ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Operating Income
Profit from core operations after operating expenses, before interest and taxes.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$39.62M, compared with -$32.72M a year earlier. Trailing-twelve-month operating income was -$149.91M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 11 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -0.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.62M-14.7% QoQ
- Last fiscal yearDec 2025
- -$143M-0.1% YoY
- LTMMar 2026
- -$149.91M-2.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -21.1% | +100.0% | +121.1 pp |
| 1 year | -0.1% | +100.0% | +100.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (143M) USD
- Year-over-year change
- -0.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (143M) | -0.1% |
| FY2024 | 2024-12-31 | (142.9M) | -29.0% |
| FY2023 | 2023-12-31 | (110.78M) | -20.7% |
| FY2022 | 2022-12-31 | (91.77M) | -16.4% |
| FY2021 | 2021-12-31 | (78.87M) | — |
Operating Income vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 operating income of -$149.91M is the 7th highest of the 11 companies compared; the peer median is -$140.27M.
- Its year-over-year change of -2.2% is the 4th highest of 11, against a peer median of -23.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$28.27M | -34.5% | — | — | |
| LTM Mar 2026 | -$47.93M | -53.5% | — | — | |
| LTM Mar 2026 | -$63.66M | +36.0% | — | 40.5% | |
| LTM Sep 2026 | -$135.36M | -20.6% | — | — | |
| LTM Jun 2026 | -$137.63M | +38.7% | — | 81.0% | |
| LTM Mar 2026 | -$142.91M | -25.7% | — | — | |
| LTM Mar 2026 | -$149.91M | -2.2% | — | — | |
| LTM Mar 2026 | -$156.87M | -11.7% | — | — | |
| LTM Mar 2026 | -$156.98M | -38.2% | — | 726.3% | |
| LTM Mar 2026 | -$170.85M | -30.3% | — | 344.6% | |
| LTM Mar 2026 | -$223.53M | +35.0% | — | 102.9% | |
| Peer median (excluding ORIC) | -$140.27M | -23.1% | — | 102.9% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| Weighted Avg Shares | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
| Weighted Avg Shares (Diluted) | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.